NewBiologix and Synastra Biotechnology struck an agreement to develop a stable producer cell line for Synastra’s investigational Duchenne muscular dystrophy (DMD) rAAV gene therapy program. Under the deal, NewBiologix will use its Xcell stable manufacturing platform to build and characterize a research cell bank, with an option to transition to a commercial license. DMD is an X-linked disorder affecting roughly 1 in 5,000 male births, with systemic gene therapy typically requiring high rAAV vector doses. Synastra and NewBiologix framed stable, genetically defined producer cell lines as a way to improve reproducibility and scale while reducing cost and complexity versus repeated transient transfection. The collaboration combines Synastra’s genomic engineering and vector design capabilities with NewBiologix’s rAAV manufacturing technology, aiming to support progression toward clinical translation. For the rAAV supply chain, the agreement illustrates how early process development is becoming a decisive differentiator in rare-disease gene therapy programs.